(Q35180069)

English

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Hervé Avet-Loiseau

26

object named as

Hervé Avet-Loiseau

0 references

19

object named as

Cyrille Hulin

0 references

25

object named as

Xavier Leleu

0 references

object named as

Michel Attal

5

0 references

Norma C. Gutiérrez

object named as

Norma Gutierrez

20

0 references

object named as

Michele Cavo

2

0 references

Jesús San Miguel

object named as

Jesus san Miguel

15

0 references

Pieter Sonneveld

3

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Hartmut Goldschmidt

7

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Antonio Palumbo

10

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

21

object named as

Thierry Facon

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Philippe Moreau

1

object named as

Philippe Moreau

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Henk M. Lokhorst

17

object named as

Henk Lokhorst

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Bronno van der Holt

11

object named as

Bronno van der Holt

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Lotfi Benboubker

23

object named as

Lotfi Benboubker

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

9

object named as

Gerald Marit

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

12

object named as

Joan Bladé

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Maria Teresa Petrucci

13

object named as

Maria Teresa Petrucci

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Francesca Patriarca

16

object named as

Francesca Patriarca

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

18

object named as

Elena Zamagni

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jean-Luc Harousseau

24

object named as

Jean-Luc Harousseau

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Juan José Lahuerta

8

object named as

Juan Jose Lahuerta

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Laura Rosinol

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Annalisa Pezzi

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Kai Neben

14

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Denis Caillot

22

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jean-Yves Mary

27

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

2 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

2173-2180

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Update on the initial therapy of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

13 July 2018

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

27 September 2018

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

27 September 2018

Can multiple myeloma become a curable disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

27 September 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

27 September 2018

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

27 September 2018

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879712

27 September 2018

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.53.0329

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

release_lrb65366ovanhe6ucdnpjkiejy

1 reference

https://api.fatcat.wiki/v0/release/lrb65366ovanhe6ucdnpjkiejy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35180069&oldid=1858320727"